HBME-1、CK19、Gal-3、ki-67在甲状腺乳头状病变中的表达  

Expression of HBME-1,CK19,Gal-3 and Ki-67 in papillary thyroid lesions

作　　者：李楠[1] 杜金荣[1] 

机构地区：[1]哈尔滨医科大学第二临床医学院病理科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2010年第6期575-578,共4页Journal of Harbin Medical University

摘　　要：目的了解HBME-1、CK19、Gal-3、Ki-67在甲状腺乳头状病变中的表达状态,并探讨这几种抗体联合的诊断价值。方法采用自制组织芯片及免疫组化检测甲状腺乳头状病变组织(甲状腺乳头状癌55例,良性病变81例)HBME-1、CK19、Gal-3、Ki-67的表达。结果 HBME-1、CK19、Gal-3、Ki-67在甲状腺乳头状癌的阳性表达率分别为94.5%、98.2%、94.6%、100%;在甲状腺良性病变阳性表达率分别为12.3%、12.5%、9.9%、33%;3种抗体在甲状腺乳头状癌和良性病变的阳性表达存在统计学差异(P<0.05)。HBME-1联合CK19、Gal-3检测在鉴别甲状腺乳头状癌与良性病变时的敏感性、特异性、诊断正确率、阳性预测值和阴性预测值分别为98.11%、90.91%、93.85%、88.14%、98.59%。结论 HBME-1联合CK19、Gal-3、Ki-67所构成的免疫组化组合是甲状腺乳头状癌与良性病变的诊断的有用标志物,尤其在鉴别诊断中具有重要价值。Objective To investigate the usefulness of immunohistochemical expression and immunolocalization of a panel of papillary lesions of thyroid markers including HBME-1、CK19、Galectin-3 and Ki-67.Methods By manual tissue chip technique and immunochemical EnVision method,the expression of HBME-1,CK19,Galectin-3 and Ki-67 were detected in papillary lesions of thyroid,including 55 with papillary thyroid carcinoma and 81 papillary thyroid hyperplasia.Results The positive rates for HBME-1,CK19,Gal-3 and Ki-67 in the papillary thyroid carcinoma were 94.5%,98.2%,94.6%,100%,which were significantly higher than those in the papillary thyroid hyperplasia（12.3%,12.5%,9.9%,33%）（P0.05）.Conclusion HBME-1、CK19、Gal-3 and Ki-67 are useful markers to distinguish the papillary thyroid carcinoma from papillary thyroid hyperplasia,especially combined application.

关 键 词：甲状腺乳头状病变 HBME-1 CK19 GAL-3 KI-67 组织芯片 

分 类 号：R446.6[医药卫生—诊断学] R581[医药卫生—临床医学]